Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database.

Cihoric, Nikola; Vlaskou Badra, Eugenia; Tsikkinis, Alexandros; Prasad, Vikas; Kroeze, Stephanie; Igrutinovic, Ivan; Jeremic, Branislav; Beck, Marcus; Zschaeck, Sebastian; Wust, Peter; Ghadjar, Pirus (2018). Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. Radiation oncology, 13(1), p. 113. BioMed Central 10.1186/s13014-018-1057-3

[img]
Preview
Text
s13014-018-1057-3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (812kB) | Preview

BACKGROUND The goal of this study is to evaluate the status and future perspectives of clinical trials on positron emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes. METHODS The www.ClinicalTrials.gov database was searched on the 20th of January 2017 for all trials containing terms describing "prostate cancer" (prostate, prostatic, malignant, malignancy, cancer, tumor) and "positron emission tomography". In total 167 trials were identified. Trials that included diseases other than PCa were excluded (n = 27; 16%). Furthermore, we excluded trials (n = 4, 2%) withdrawn prior to first patient enrollment. The remaining trials (n = 137, 82%) were selected for further manual classification analysis. RESULTS One hundred thirty-seven trials were detected and analyzed. Majority of trials were in "active" recruitment status (n = 46, 34%) followed by trials that had been "completed" - (n = 34, 25%) and trials with "closed recruitment but active follow-up" (n = 23, 17%). Phase 1 and 2 comprised 46% of the complete trial portfolio. Locally confined disease was of major interest (n = 46, 34%), followed by metastatic disease - not otherwise specified (n = 43, 13%). Evaluation of PET was the primary goal of the trial in 114 (83%) cases. Most of the trials evaluated only one agent (n = 122, 89%). Choline and PSMA represented two major groups (total 50%) and they were equally distributed across trial portfolio with 25% (n = 34) each. PSMA trials showed the highest average annual growth rate of 56%. The trials were conducted in 17 countries. CONCLUSION The scientific community is showing a strong and ever-growing interest in the field and we expect that in the coming years, more phase III trials will be initiated ultimately delivering the required Level 1 evidence.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Cihoric, Nikola; Vlaskou Badra, Eugenia; Tsikkinis, Alexandros and Ghadjar, Pirus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1748-717X

Publisher:

BioMed Central

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

21 Jun 2018 10:05

Last Modified:

25 Oct 2019 11:02

Publisher DOI:

10.1186/s13014-018-1057-3

PubMed ID:

29914515

Uncontrolled Keywords:

Cancer of prostate Cancer of the prostate Neoplasms, prostate Neoplasms, prostatic Pet Positron emission Positron emission tomography Prostate cancer Prostate neoplasms Prostatic cancer

BORIS DOI:

10.7892/boris.117315

URI:

https://boris.unibe.ch/id/eprint/117315

Actions (login required)

Edit item Edit item
Provide Feedback